Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 137.50 135.00 140.00 137.50 135.00 137.50 60,429 08:00:29
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 6.1 -13.9 -35.9 - 78

Reneuron Share Discussion Threads

Showing 8251 to 8273 of 8275 messages
Chat Pages: 331  330  329  328  327  326  325  324  323  322  321  320  Older
DateSubjectAuthorDiscuss
12/4/2021
15:01
...and zho. ...and those who pushed it up on Friday, ignorant, I'm sure, that the article would appear over the weekend.
dickbush
12/4/2021
10:27
My thanks to Richard Griffiths and the Mail on Sunday.
dickbush
11/4/2021
08:37
Former City broker Richard Griffiths has been dubbed the ‘Welsh Wizard’ for his stock market bets, and has brought plenty of fellow investors under his spell. So market watchers take note. It has emerged that the Jersey dweller has taken a 7 per cent stake in ReNeuron. The small-cap is a stem cell research specialist which recently raised £15 million to expand a study of its treatment for a degenerative eye disease. The shares have rallied over the last month, up more than 30 per cent at £1.33. Griffiths’ followers will have their eyes trained on this one https://www.thisismoney.co.uk/money/markets/article-9457285/STOCK-WATCH-whos-favourite-William-Hill-takeover.html
zho
09/4/2021
17:56
Breakout to a new 50 day high on good volume. Looks primed for a move up.
x54v
09/4/2021
17:39
Looking good for Monday. Another Holdings RNS maybe ??
bradders51
09/4/2021
14:28
There may not be much progress on the operating front but, at least, the share price is.
dickbush
09/4/2021
13:33
Are we looking at breakout at the end of one of those flag thingies? If so, my boots will be readied for filling.
small crow
08/4/2021
16:00
Their schedule has slipped again. They have still only treated 3 people in the Ph2a extension. Could this go any slower!
whatno
06/4/2021
12:02
ShareTalk with Olav today hxxps://www.share-talk.com/olav-hellebo-ceo-of-reneuron-group-plc-rene-l-interview/#gs.xjequd Shame nothing about exosome technology.
bradders51
06/4/2021
11:11
agreed its time for the rubber to hit the road
martinfrench
31/3/2021
09:15
We sound like a solution looking for a problem all the time? - Seems to be a continuous dialogue to keep the funds flowing? - When do we set sail?
deutsch4
31/3/2021
00:05
https://uk.advfn.com/stock-market/london/reneuron-RENE/share-news/ReNeuron-Group-plc-CTX-cell-line-shows-further-pot/82398633 ReNeuron Group plc 07 May 2020 ReNeuron Group plc CTX cell line shows further potential ReNeuron's CTX cell line shows further potential Newly published positive efficacy data in an accepted model of Huntington's disease ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that new positive data relating to its CTX cell therapy candidate have been published in the leading peer-reviewed scientific journal Stem Cells, in a paper entitled "Implantation of the clinical-grade human neural stem cell line, CTX0E03, rescues the behavioural and pathological deficits in the quinolinic acid-lesioned rodent model of Huntington's disease". The new data show for the first time that ReNeuron's CTX human neural stem cell line can rescue deficits associated with an accepted animal model of Huntington's disease, a progressive genetic brain disorder. This study was led by Professor Jihwan Song from the Department of Biomedical Science at the CHA University in South Korea and the paper is accessible at the following link: https://stemcellsjournals.onlinelibrary.wiley.com/doi/10.1002/stem.3191 [ ... ]
supernumerary
30/3/2021
23:45
There was some pre-clinical work done by a Professor at a university in South Korea a few years back.
whatno
30/3/2021
23:20
Do we have a HD product?
the stigologist
30/3/2021
20:06
While I'm on the subject :¬) There's an open goal awaiting the right striker... https://www.fiercebiotech.com/biotech/wave-culls-leading-huntingdon-meds-as-shares-go-under-after-rival-roche-hit-by-similar-fate Wave culls leading Huntington's meds as shares go under after rival Roche hit by similar fate Just over a year after Wave Life Sciences cut staffers, threw out a Duchenne muscular dystrophy med and saw its Huntington's disease drug flop in a key test, the waves come crashing down again for the biotech. In an update posted after-hours Monday evening, Wave said data out of a midstage tests for two of its Huntington’s drugs, WVE-120102 and WVE-120101, were simply too poor to keep going, and they have been axed. WVE-120102 works as an antisense oligonucleotide designed to stop the body from making a mutant huntingtin (mHTT) protein linked to the disease. The writing was already on the wall for the experimental drug after it failed to beat or match Roche and Ionis’ rival Huntington’s med tominersen. WVE-120101, meanwhile, also works as an antisense oligonucleotide and interferes with the mutant mRNA copy of the huntingtin (HTT) gene. It does this by binding to the mutant mRNA, preventing the cell’s protein-making machinery from reading it. This prevents abnormal Huntingtin protein from being produced. Across two trials, however, the drugs failed to perform. In the so-called PRECISION-HD2 core trial, results from all participants (88 in total) showed “no statistically significant change” in mHTT when pitted against a dummy treatment, either with single or multiple doses of WVE-120102. In an open-label test, too, the data were poor and “inconsistent,” the biotech said. A similar testing theory was also behind its other asset WVE-120101, and, because of the failure seen for the former drug, the biotech is also cutting its losses here. “Given these and results from Wave’s previous clinical trials, as well as current understanding of the limitations of the company’s first-generation candidates, Wave will also stop clinical development of WVE-120101,” the company said in a statement. This is a notoriously tough area: Huntingdon’s disease has few success stories in R&D and is a tricky target. Just ask Roche and Ionis, which earlier this month stopped work on tominersen, also known as IONIS-HTTRx and RG6042, which is designed to reduce production of HTT. [ ... ]
supernumerary
30/3/2021
09:09
Closer yes. Lets hope it's not already in his pocket?
deutsch4
30/3/2021
07:29
Would he keep buying on poor expectations? Bet he’s closer to the action than we are.
rayrac
30/3/2021
07:19
Good to see Griffiths taking more shares
ayl30
24/3/2021
09:15
The product we focus on here changes all the time. Hand sanitiser next? - Hop, skip, but no jump?
deutsch4
23/3/2021
16:36
https://www.fiercebiotech.com/biotech/roche-halts-huntington-s-phase-3-ionis-partnered-antisense-drug-after-interim-review Roche has stopped a phase 3 Huntington’s disease clinical trial after an interim review of the data. The preplanned review found no new safety signals associated with Ionis Pharmaceuticals-partnered antisense drug tominersen, suggesting lack of efficacy may have driven the decision to stop the trial. Tominersen, also known as IONIS-HTTRx and RG6042, is designed to reduce production of HTT, the protein that in its mutated form drives the rare genetic, progressive condition Huntington’s. HTT is a validated target, but difficulties drugging the protein via traditional modalities means there remains a major unmet need in Huntington’s, leading companies including Ionis to try to come at the problem from a new angle. Ionis’ work led to a licensing deal with Roche in 2017 and forecasts of $5 billion peak annual sales for antisense therapy tominersen. “Given the unmet medical need, with no therapies approved to slow progression of this rare disease, tominersen was widely acknowledged to be a potential high risk but blockbuster reward asset in Roche's pipeline,” analysts at Jefferies wrote in a note to investors. [ ... ] The failure of tominersen creates a potential opportunity for other developers of Huntington’s drugs. Wave Life Sciences and Takeda are partnered on two antisense therapies that are in phase 1/2 trials. Takeda also recently picked up a preclinical mRNA translation modulator through a deal with Anima Biotech, and Arvinas is exploring the application of its protein degradation platform to the disease.
supernumerary
22/3/2021
12:07
I think the recent major holding RNS's tell a different story.
bradders51
22/3/2021
11:09
Supernumary - I agree with your sentiments. We all live in hope that "this time it will be different" but you can't ignore Rene's poor track record on delivery. I think the fact that Michael Hunt, CFO & chief cheerleader, is leaving says alot.
onceaday
22/3/2021
09:09
Just sold my last lot of these. Never seems to deliver the goods
volsung
Chat Pages: 331  330  329  328  327  326  325  324  323  322  321  320  Older
ADVFN Advertorial
Your Recent History
LSE
RENE
Reneuron
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210413 14:28:21